特发性肺纤维化患者肺功能变化与死亡风险
基于特发性肺纤维化前瞻性结局登记研究,纳入在入组中心6个月内诊断或确认的IPF患者1001例,中位随访38.4个月,采用含时间依存协变量的Cox比例风险模型评估FVC或Dlco占预计值百分比首次下降≥2%、≥5%、≥10%(Dlco另含≥15%)与后续死亡或肺移植风险的关联。未调整和调整分析中所有阈值下降均与死亡或肺移植风险显著相关;调整后FVC下降≥2%、≥5%、≥10%分别与风险升高1.8倍、2.3倍、2.7倍相关,Dlco下降≥2%、≥5%、≥10%、≥15%分别与风险升高2.0倍、1.4倍、1.5倍、1.9倍相关。Dlco相对下降较绝对下降风险升高更明显,FVC无此现象。作者认为即使小幅下降也有预后意义。
要点
- 调整分析中FVC占预计值百分比绝对下降≥2%、≥5%、≥10%分别与后续死亡或肺移植风险升高1.8倍、2.3倍、2.7倍相关。
- 调整分析中Dlco占预计值百分比绝对下降≥2%、≥5%、≥10%、≥15%分别与后续死亡或肺移植风险升高2.0倍、1.4倍、1.5倍、1.9倍相关。
- 未调整和调整分析中所有FVC和Dlco下降阈值均与死亡或肺移植风险显著相关。
- Dlco按相对下降定义阈值时风险升高一般大于绝对下降,FVC无此现象。
- 作者认为IPF患者FVC和Dlco占预计值百分比即使小幅下降也能提示预后。
适用人群与场景
- 在入组中心6个月内诊断或确认的特发性肺纤维化(IPF)患者,来自特发性肺纤维化前瞻性结局登记研究,共1001例。
诊断标准与关键阈值
- FVC或Dlco占预计值百分比首次下降阈值:≥2%、≥5%、≥10%,Dlco另含≥15%。
研究设计与关键结果
- 研究类型:特发性肺纤维化前瞻性结局登记研究;样本量1001例;中位随访38.4个月。
- 采用含时间依存协变量的Cox比例风险模型,评估FVC或Dlco占预计值百分比首次下降≥2%、≥5%、≥10%(Dlco另含≥15%)与后续死亡或肺移植风险的关联;模型未调整或调整FVC和Dlco占预计值百分比、年龄、性别、吸烟状态、BMI、抗纤维化治疗(是或否)及入组时氧疗。
- 未调整和调整分析中,所有FVC和Dlco占预计值百分比下降阈值均与死亡或肺移植风险显著相关。
- 调整分析中,FVC占预计值百分比绝对下降≥2%、≥5%、≥10%分别与后续死亡或肺移植风险升高1.8倍、2.3倍、2.7倍相关。
- 调整分析中,Dlco占预计值百分比绝对下降≥2%、≥5%、≥10%、≥15%分别与后续死亡或肺移植风险升高2.0倍、1.4倍、1.5倍、1.9倍相关。
- Dlco按相对下降定义阈值时风险升高一般大于绝对下降,FVC无此现象。
证据类型、等级与局限
- 证据类型:前瞻性登记研究(特发性肺纤维化前瞻性结局登记研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,IPF患者FVC和Dlco占预计值百分比即使小幅下降也能提示预后。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease associated with lung function decline and high mortality.
RESEARCH QUESTION: What are the associations between thresholds of lung function decline and the risk of mortality in patients with IPF?
STUDY DESIGN AND METHODS: The Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry enrolled patients with IPF that was diagnosed or confirmed at the enrolling center within the prior 6 months. Associations between time to first decline in FVC or diffusing capacity of the lungs for carbon monoxide (Dlco) of ≥ 2% predicted, ≥ 5% predicted, and ≥ 10% predicted (and ≥ 15% predicted for Dlco) and risk of subsequent death or lung transplantation was assessed using Cox proportional hazards models with a time-dependent covariate. Models were unadjusted or adjusted for FVC and Dlco % predicted, age, sex, smoking status, BMI, antifibrotic treatment (yes or no), and oxygen use at enrollment.
RESULTS: Among 1,001 patients, median follow-up time was 38.4 months. Significant associations were observed between all thresholds of decline in FVC and Dlco % predicted and the risk of death or lung transplantation in unadjusted and adjusted analyses. In adjusted analyses, absolute declines in FVC of ≥ 2% predicted, ≥ 5% predicted, and ≥ 10% predicted were associated with 1.8-fold, 2.3-fold, and 2.7-fold increases in the risk of subsequent death or lung transplantation, whereas absolute declines in Dlco of ≥ 2% predicted, ≥ 5% predicted, ≥ 10% predicted, and ≥ 15% predicted were associated with 2.0-fold, 1.4-fold, 1.5-fold, and 1.9-fold increases in the risk of subsequent death or lung transplantation, respectively. For Dlco, but not FVC, the increase in risk generally was greater for patients meeting a threshold based on a relative rather than an absolute decline.
INTERPRETATION: Our results show that even small declines in FVC and Dlco % predicted inform prognosis in patients with IPF.
CLINICAL TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01915511; URL: www.
CLINICALTRIALS: gov.
参考来源
- Oldham JM, Neely ML, Wojdyla DM, et al. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2025. PMID: 40020995. doi:10.1016/j.chest.2025.02.018
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。